Recombinant 14-valent human papillomavirus vaccine (type 6,11,16,18,31,33,35,39,45,51,52,56,58,59, Sinocelltech Inc)
重组十四价人乳头瘤病毒疫苗（6,11,16,18,31,33,35,39,45,51,52,56,58,59型，神州细胞工程）
Report date: 2023/08/15 20:01:07
Base Information
Drug NameRecombinant 14-valent human papillomavirus vaccine (type 6,11,16,18,31,33,35,39,45,51,52,56,58,59, Sinocelltech Inc)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[9]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Nuoning Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesBeijing Nuoning Biotechnology Co LtdSinoCelltech Ltd
Inactive CompaniesN/A
Active Indications +[9]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A